Quote:Posted On: 06/23/2015 12:23:27 PM
Posted By: 4kids
Re: Renz #20429
because every time a colluding entity wash traded PTOI in the last 6 to 9 months
.. part of their *wash traded* pool >> got picked off by P2O investors
i'll take low to no volume from now till mgmt files
but i suspect we see *volume* within a week's time frame
and it will be interesting to see if it's another *round* of imo that 1M cert
accessed EO 2014 (Seneca's) .. 150k to 200k .. *utilized*
edit >> and if another *block* is utilized >> it will telling to see *if marked* .. or not
(reminder 5.26.15 tape and then 6.8.15 and 6.12.15)
colluding entities have a real problem .. with avgs .. (90 day in particular)
btw .. imo based on interacting with many P2O investors .. most (not all) have
DCA'd *shares* over the last few years ... and are content to patiently bide
their time .. essentially >> certain P2O investors have turned the table on those
who collude
they continue to provide bid support (or as i call it speed bumps) which have to be filled
in total b4 taking PTOI *lower*
and imo most P2O investors understand the drill that hitting the ask just aids
and abets (easier to reset)
i'm watching the bid creep ever upward as YOY %s are about to go GREEN
not for anything but it was Dec 2013 .. (18 months ago) that that last *round*
kicked in .. and i CANT help but appreciate the irony in play/place
of wasted *efforts* .. (essentially greed coupled with stupidity)
prior *round* was RH's lack of a honeymoon (mid Aug 2013 to early Dec 2013)
i also strongly suspect they (colluders) are dancing ever closer to triggering threshold ..
which imo will SHOW (for the 3rd time on PTOI) within 6 days of mgmt's next material event filed
(re: pilot and/or monies transferred)
i have to be specific since every word is parsed by the CON side of the original crew >> *elsewhere* ..
4kids
4kids - Will you please define, with examples, the terms
Top 10 Most Recent News Articles
Servier's Data on Tovorafenib Shows Promise in pLGG
New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...
Continue Reading
YSTUDIO's Pens: A Nod to the Power of Writing
Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...
Continue Reading
CARsgen's CAR-T Breakthrough on China's Insurance List
A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...
Continue Reading
HONGQI's EHS4 Launch in Europe: Bridging East and West
Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...
Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results
Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...
Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale
Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...
Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut
Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...
Continue Reading
PASCAL's Holiday Gift Edit: Timeless Watches Shine
Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...
Continue Reading
Luvme Hair Offers Wig Variety for Winter Fashion
Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...
Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives
Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...
Continue ReadingTop 5 Most Recently Viewed Articles
Prudent Growth Partners Expands with Castle Shops Acquisition
Prudent Growth Partners Enhances Retail Portfolio Prudent Growth Partners, LLC, a well-established private equity real estate firm, has recently made a significant leap forward by acquiring Castle Shops for $5.4 million. This 37,309 square foot retail center is situated in a bustling area, presenting exciting opportunities for growth and development. Strategic Location of...
Continue Reading
TOYO Co., Ltd Unveils Ambitious Solar Manufacturing Project
TOYO Co., Ltd Unveils Plans for Solar Manufacturing Facility TOYO Co., Ltd (NASDAQ: TOYO), a leading company specializing in solar solutions, is thrilled to reveal its plans for a cutting-edge solar cell manufacturing facility. This new plant is expected to have an impressive annual capacity of 2 gigawatts (GW), reflecting TOYO's commitment to advancing renewable energy...
Continue ReadingFuture Trends in the AI Semiconductor Ecosystem Explained
Understanding the AI Semiconductor Ecosystem The AI semiconductor ecosystem is evolving rapidly, a movement driven largely by the increasing need for computational power essential for artificial intelligence advancements. This sector has reached a pivotal point where the demand for AI-powered solutions, especially large language models, significantly exceeds current chip...
Continue Reading
Broadwind Set to Release Year-End 2024 Results Soon
Broadwind's Upcoming Financial Results Announcement Broadwind (Nasdaq: BWEN), a leading precision manufacturer known for its specialized components and solutions, has exciting news. They are set to announce their financial results for the fourth quarter and full year of 2024. This important update will occur before the market begins on a scheduled day. Conference Call...
Continue Reading
Snowflake Stock Earnings Rollercoaster: The Good and Bad
Rocky Road for Snowflake: Earnings Highlights Turn the lights on, folks. Right when you thought Snowflake was ready to soar, the stock pulled some classic market gymnastics. This company just reported a fourth-quarter revenue of $1.28 billion, which isn't just pocket change; that’s $50 million over what the analysts were slinging around, estimating a mere $1.26 billion...
Continue Reading